CD274 and cancer: The checkpoint molecules including cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1), together with programmed death-ligand 1 (PD-L1) have been successfully targeted and antibodies affecting these molecules have been approved by the US Food and Drug Administration for therapy against several cancer types.